锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月27日南向资金减持62.6万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金增 持的有2天，累计净增持457.23万股。近20个交易日中，获南向资金增持的有12天，累计净增持948.58万 股。截至目前，南向资金持有锦欣生殖（01951.HK）14.63亿股，占公司已发行普通股的53.03%。 ...

根据招股书披露的财务数据，锦欣康养在业务扩张的同时，盈利能力持续增强，规模效应正逐步显现。 来源：康养新天地 据港交所2月25日消息，锦欣康养产业集团有限公司（以下简称"锦欣康养"）向港交所主板递交上市申 请，中金公司、广发证券为联席保荐人。 这家依托锦欣集团70余年医疗积淀、于2011年切入养老赛道的康养企业，正在努力叩开资本市场的大 门。 锦欣集团 截至2025年9月30日，锦欣康养已设立或收购23家医疗养老结合设施，业务覆盖川渝地区、长三角地区 及大湾区。提供的服务内容包括住宿、专业护理、营养管理、社交文娱、医疗服务、康复辅助及个性化 按需服务等综合性照护，同时也通过社区及居家养老服务将覆盖范围延伸至机构之外。 营收方面，2023年全年为约4.89亿元，2024年增长至约6.05亿元，同比增长23.7%；2025年前九个月实 现营收约5.47亿元，较2024年同期4.48亿元亦有增长。 盈利方面，2023年全年期内利润为2706.2万元，2024年增至4031万元，同比增长约48.9%，增速显著高 于收入增速；2025年前九个月期内利润为2610.6万元。 毛利率方面，2023年为21.7%，2024年 ...

格隆汇2月23日丨锦欣生殖(01951.HK)公告，公司谨订于2026年3月26日(星期四)举行董事会会议，藉以 (其中包括)考虑及批准集团截至2025年12月31日止年度的年度业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited * 錦欣生殖醫療集團有限公司*（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈，本公司謹訂於2026年3月26日（星期四）舉行董事會會議，藉以 （其中包括）考慮及批准本集團截至2025年12月31日止年度的年度業績及其發佈。 承董事會命 錦欣生殖醫療集團有限公司* 首席執行官、代理首席財務官兼執行董事 董陽 香港，2026年2月23日 於本公告日期，本公司董事會包括執行董事董陽先生、呂蓉女士及耿麗紅博士；主席兼 非執行董事鍾勇先生；及非執行董事胡喆女士、嚴曉晴女士及陳樹云先生；以及獨立非 執行董事莊一強博士、李建偉先生、王嘯波先生及葉長青先生。 * 僅供識別 1951 董事會會議日期 ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 2.727 million shares on February 13, 2026, while experiencing a net reduction of 13.909 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have increased their holdings in Jinxin Reproductive Medicine on 15 occasions, resulting in a total net increase of 24.1786 million shares [1] - As of now, southbound funds hold 1.461 billion shares of Jinxin Reproductive Medicine, accounting for 52.97% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, obstetrics and pediatrics medical services, as well as the sale of medical consumables and equipment [2] - The company's services are mainly provided in China and the United States [2]

Group 1 - The core point of the article highlights that southbound funds reduced their holdings in Jinxin Reproductive Medicine (01951.HK) by 4.8555 million shares on February 11, with a total net reduction of 5.5385 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds increased their holdings on 14 days, resulting in a cumulative net increase of 19.0741 million shares [1] - As of now, southbound funds hold 1.466 billion shares of Jinxin Reproductive Medicine, accounting for 53.15% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, and maternal and pediatric medical services, as well as the sale of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

Core Viewpoint - Southbound funds have increased their holdings in Jinxin Fertility (01951.HK), indicating growing investor interest in the company and its services in the assisted reproductive sector [1] Group 1: Shareholding Activity - On February 10, southbound funds increased their holdings by 679,000 shares of Jinxin Fertility [1] - Over the past five trading days, there have been four days of net increases in holdings, totaling 3.4365 million shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 20.0356 million shares [1] - Currently, southbound funds hold 1.471 billion shares of Jinxin Fertility, representing 53.33% of the company's issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and obstetrics and pediatrics medical services [1] - Jinxin Fertility operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [1]

Group 1 - Southbound funds reduced their holdings in Jinxin Fertility (01951.HK) by 4.7445 million shares on February 9 [1] - Over the past 5 trading days, southbound funds increased their holdings on 4 days, with a total net increase of 13.3475 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, totaling 13.3616 million shares [1] - Currently, southbound funds hold 1.47 billion shares of Jinxin Fertility, accounting for 53.31% of the company's issued ordinary shares [1] Group 2 - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [1] - The company primarily operates in China and the United States [1]

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 2.947 million shares on February 5, with a total net increase of 17.619 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have increased their holdings on 13 days, resulting in a cumulative net increase of 16.8501 million shares [1] - As of now, southbound funds hold 1.474 billion shares of Jinxin Reproductive Medicine, accounting for 53.45% of the company's total issued ordinary shares [1] Group 2 - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as the sale of medical consumables and equipment [1] - The company's services are mainly provided in China and the United States [1]